Buy & Sell HCA Health Inc (HCA) – HCA Health Inc Price Today
Aura AI Summary
Key Stats
- $94.85BMarket Cap
- HealthSector
- -21.79%3M Drawdown
- $143.75BEnterprise Value
- 0.73%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 70 daysTypical Hold Time
HCA Health Inc (HCA) is currently valued at a market capitalization of $94.85B, with an enterprise value of $143.75B. Over the past 52 weeks, HCA Health Inc has traded between a low of $334.32 and a high of $545.13, highlighting its annual price range. Over the past three months, HCA Health Inc has recorded a drawdown of -21.79%, reflecting recent price volatility. HCA Health Inc offers a dividend yield of 0.73%, with the most recent dividend of $0.78 paid on 17 Mar 26. On average, investors hold HCA Health Inc for approximately 70 days, indicating typical investor behavior on the platform.
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Most Recent News
Altice France extends exclusivity period for Bouygues Telecom, Free-iliad, and Orange until June 5, 2026.
Altice France has extended the exclusivity period granted to Bouygues Telecom, Free-Groupe iliad, and Orange for their joint offer to acquire certain Altice France assets. The initial exclusivity was set to expire on May 15, 2026, but has now been pr...
Skanska wins SEK 1.9 billion contract for construction starting August 2026
Skanska has secured a construction contract worth approximately SEK 1.9 billion with an unnamed client. The project is scheduled to begin in August 2026 and is expected to be completed by the first quarter of 2029. This contract will be included in S...
Novo Nordisk shares jump 25% on new oral Ozempic and Wegovy launches and FDA approvals
Novo Nordisk's stock surged 25% in the past month, recovering from multi-year lows due to the launch of oral versions of its Ozempic and Wegovy weight loss drugs, FDA approvals, and telehealth partnerships. The company also slightly raised its sales ...